Nehal Lakhani, MD
Hematology & Oncology · Grand Rapids, MINPI 1598986986
Payments from drug & device makers
Across 2,345 payments — averaging $6390.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2.2M
- Seagen Inc.$2.2M
- Merck$2M
- Regeneron$1.9M
- Janssen Research & Development, LLC$1.6M
- Pfizer$1.1M
- plus $4M from 24 others
Across 90 payments — averaging $269.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$17K
- Pfizer$3K
- Orphai Therapeutics Inc.$2K
- Servier Bioinnovation$1K
- Servier Pharmaceuticals LLC$296
- AbbVie$85
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 23 | $2,224,925 |
| Seagen Inc. | 417 | $2,216,087 |
| Merck | 502 | $2,016,571 |
| Regeneron | 351 | $1,893,674 |
| Janssen Research & Development, LLC | 120 | $1,586,690 |
| Pfizer | 106 | $1,079,986 |
| Servier Bioinnovation | 229 | $648,455 |
| SK Life Science, Inc. | 40 | $595,495 |
| E.r. Squibb & Sons, L.L.C. | 3 | $455,805 |
| Biontech SE | 116 | $425,623 |
| Bristol Myers Squibb | 8 | $347,583 |
| Incyte Corporation | 54 | $318,147 |
| Alkermes, Inc. | 60 | $228,365 |
| Genmab U.S., Inc. | 13 | $156,041 |
| Day One Biopharmaceuticals | 49 | $150,123 |
| Roche Products Limited | 80 | $148,624 |
| Helsinn Healthcare SA | 43 | $140,439 |
| GSK | 49 | $116,758 |
| Gilead | 8 | $90,054 |
| Novartis | 4 | $70,065 |
| Beigene, Ltd. | 49 | $32,997 |
| Exelixis Inc. | 6 | $24,835 |
| Amgen | 4 | $7,689 |
| Janssen Global Services, LLC | 1 | $4,935 |
| Macrogenics, Inc. | 2 | $4,242 |
| AbbVie | 1 | $350 |
| Foundation Medicine, Inc. | 3 | $260 |
| AstraZeneca | 2 | $208 |
| Boehringer Ingelheim | 1 | $103 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
How this compares
$14,985,153 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$19.1M
- Brett BrinkerGrand Rapids$2.3M
- Eric SantosGrand Rapids$1.5M
- Andrew SochackiGrand Rapids$1.4M
- Amy Vander WoudeGrand Rapids$1.2M
- Colin HardinGrand Rapids$974K
- Erin PettijohnGrand Rapids$871K
- Latha PolavaramGrand Rapids$69K
- Timothy OrourkeGrand Rapids$55K
- Hirva MamdaniDetroit$9.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.